Entrada Therapeutics, Inc.
ENTR-601-45
Duchenne muscular dystrophy
Countdown
56days
Phase 2 readout · ~ Aug 31, 2026 estimated
What's at stake
Phase 2 trial results for ENTR-601-45 in Duchenne muscular dystrophy are due ~ Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“The Company is on track to report data from Cohort 1 (5 mg/kg) in mid‑2026”